Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy

14 Jan 2019

Abstract excerpt

Abstract Purpose: We sought to determine the mechanism of an exceptional response in a patient diagnosed with a SMARCB1/INI1-negative chordoma treated with tazemetostat, an EZH2 inhibitor, and followed by radiotherapy. Patient and Methods: In an attempt to investigate the mechanism behind this apparent abscopal effect, we interrogated tumor tissues obtained over the clinical course. We utilized next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to MicroRNA in disease regulation
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30642912
DOI: 10.1158/1078-0432.ccr-18-3133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and RadiotherapyPMID 30642912Read ↗

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma XenograftSemantic proximity Read ↗

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a MatchmakerSemantic proximity Read ↗

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationSemantic proximity Read ↗

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read ↗

Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapySemantic proximity Read ↗

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read ↗

Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and increased expression of transposable elements and viral response pathwaysSemantic proximity Read ↗

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read ↗

Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.Semantic proximity Read ↗

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.Semantic proximity Read ↗

EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomasSemantic proximity Read ↗

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.